The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug –(1) Open-label, randomized and comparative study–
Phase 4
- Conditions
- Asthma
- Registration Number
- JPRN-UMIN000001006
- Lead Sponsor
- JA Tohno Kousei Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.Past treatments with anti-LT drugs in the previous 3 months. 2.Past treatments with oral corticosteroids in the previous 2 weeks. 3.Chronic obstructive lung disease (COPD) and other respitatory disease. 4.Severe liver, kidney, heart , hematic and other diseases 5.Inappropriate patients from the doctor's viewpoint.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Peripheral airway inflammation in induced sputum (Eosinophils and ECP)
- Secondary Outcome Measures
Name Time Method 1.Asthmatic symptoms and QOL(AQLQ) 2.Pulmonary functions (PEF, FEV1, FEF50,FEF75) 3.Eosinophils in peripheral blood